【摘要】 恶性胸腔积液(Malignant Pleural Effusion,MPE)对于肿瘤相关发病的一个重要的来源。当前的治疗主要是姑息治疗以及控制症状的治疗,而并没有提出胸腔积液的病理学,也不会提高生存率。进一步病理生理机制的阐明,再加上新疗法的发展,比如胸腔内靶向药物灌注化疗,极大提高我们当前的治疗疗效。血管内皮生长因子-A(VEGF-A)被认为是恶性胸腔积液形成的重要细胞因子。因此,抗血管生成药物比如贝伐单抗,一种可以抑制VEGF生物活性的单克隆抗体,可能在治疗恶性胸腔积液中有潜在的作用。更多还原

【Abstract】 Malignant Pleural Effusion(MPE) is an important source of tumor-related morbidity.The current treatment is mainly palliative care and control of symptoms,and did not put for ward the pathology of pleural effusion so it can not improve the survival rate.Further clarification of pathophysiological mechanisms,coupled with the development of new therapies,such as intracavity targeting drug infusion chemotherapy,greatly improves our current therapeutic efficacy.Vascular endothelial growth factor-A(VEGF-A) is thought to be an important cytokine in the formation of malignant pleural effusions.Thus,anti-angiogenic drugs such as bevacizumab,a monoclonal antibody that inhibits the biological activity of VEGF,may have a potential role in the treatment of malignant pleural effusions.更多还原